HCW Biologics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.1M
- Price
- $2.13
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.48%
- Volume
- 1.2M
About
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Quick stats
Shares outstanding1.6M
Computed float1.0M
Float / shares63.7%
Cash runway (months)-3.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001828673
Websitehttps://www.hcwbiologics.com
AI Summary
AI-generated1/24
majormixedearnings
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics reported Q2 2026 revenue of $135,568 and a net loss of $5.2 million, issuing a going concern warning that raises doubts about its ability to continue operations for the next 12 months without additional funding.
Clinically, the company reported preliminary positive data for its lead autoimmune candidate HCW9302, showing improvements in SALT scores without dose-limiting toxicities, and requested a pre-IND meeting for its T-cell engager program.
To maintain its listing, the company executed a 1-for-6 reverse stock split on June 30, 2026, and raised approximately $5.6 million through two private placements during the quarter.
Red flags
- Substantial doubt exists regarding ability to continue as a going concern
- Cash balance ($741k) insufficient to cover current liabilities ($18.6M)
- Reverse stock split (1-for-6) effected to maintain Nasdaq compliance